GURUFOCUS.COM » STOCK LIST » USA » NYSE » ResMed Inc (NYSE:RMD) » Definitions » Cash-to-Debt
Switch to:

ResMed (NYSE:RMD) Cash-to-Debt

: 0.15 (As of Dec. 2023)
View and export this data going back to 1995. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. ResMed's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.15.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, ResMed couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for ResMed's Cash-to-Debt or its related term are showing as below:

RMD' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.11   Med: 0.36   Max: 3.01
Current: 0.15

During the past 13 years, ResMed's highest Cash to Debt Ratio was 3.01. The lowest was 0.11. And the median was 0.36.

RMD's Cash-to-Debt is ranked worse than
89.34% of 863 companies
in the Medical Devices & Instruments industry
Industry Median: 1.94 vs RMD: 0.15

ResMed Cash-to-Debt Historical Data

The historical data trend for ResMed's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

ResMed Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cash-to-Debt
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 0.36 0.37 0.30 0.14

ResMed Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash-to-Debt Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.13 0.13 0.14 0.14 0.15

Competitive Comparison

For the Medical Instruments & Supplies subindustry, ResMed's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ResMed Cash-to-Debt Distribution

For the Medical Devices & Instruments industry and Healthcare sector, ResMed's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where ResMed's Cash-to-Debt falls into.



ResMed Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

ResMed's Cash to Debt Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

ResMed's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ResMed  (NYSE:RMD) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


ResMed Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of ResMed's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


ResMed (NYSE:RMD) Business Description

Address
9001 Spectrum Center Boulevard, San Diego, CA, USA, 92123
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Executives
Brett Sandercock officer: Chief Financial Officer 17 GUINEVIERE COURT, CASTLE HILL, NEW SOUTH WALES C3 2154
Michael J. Farrell officer: Chief Executive Officer C/O REMED INC, 9001 SPECTRUM CTR. BLVD., SAN DIEGO, CA 92123
Michael J Rider officer: Global General Counsel 9001 SPECTRUM CENTER BLVD, SAN DIEGO CA 92123
Robert Andrew Douglas officer: President and COO 21 ATTUNGA ROAD, NEWPORT, NEW SOUTH WALES C3 2106
Kaushik Ghoshal officer: President, SaaS Business 9001 SPECTRUM CENTER BLVD, SAN DIEGO CA 92123
David Pendarvis officer: Chief Administration Officer REDMED INC, 14040 DANLELSON ST, POWAY CA 92064
Karen Drexler director C/O DIADEXUS, INC., 343 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Justin Leong officer: President, Asia and LATAM C/O RESMED INC, 9001 SPECTRUM CENTER BLVD, SAN DIEGO CA 92123
Desney Tan director 9001 SPECTRUM CENTER BLVD, SAN DIEGO CA 92123
John Hernandez director 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA 92123
Lucile Blaise officer: President, Sleep & RC Business RESMED INC., 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA 92123
Peter C Farrell director RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857
James Hollingshead officer: President, Sleep Business C/O RESMED INC., 9001 SPECTRUM CENTER BOULEVARD, SAN DIEGO CA 92123
Carol Burt director C/O WELLCARE HEALTH PLANS, INC., 8725 HENDERSON ROAD, TAMPA FL 33634
Resmed Inc director 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA 92123